Pharma friendless on Facebook | DTC ad spending flat | Rate of healthcare marketing and advertising falls | Consumers chose food over meds | Some see light at tunnel's end
"It ain't pretty," as the private detectives say in pulp fiction. Of course, Pharmaceutical Executive's Agency Confidential investigates healthcare advertising not crime scenes. And so far we haven't tripped over any corpses. What we have found while snooping around the industry's top agencies are a set of some pretty dim stats. Consider:
Trimming the sails means doing things differently. Pharmaceutical companies are changing their advertising mix. Less money is going to print ads in magazines and newspapers and more money is going into television and online ads.
IMS Health reports that the typical return on DTC investment ranges from 1.9 for syndicated TV to 1.4 for network television.
But enough with the stats, you get the picture—Things are tight and pharma is trying to get it right.
In this year's Agency Confidential, Agency Insider Mark Chataway travels the Internet Super Highway. Read what he found in "I've Seen The Revolution And It's Not Working". In Agency Buzz, 21 top agency executives tell what they really think about the marketing and regulatory environment. But they don't leave you hanging. They'll tell you how to survive.
– Marylyn Donahue, Special Projects Editor
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.